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Abstract
Aim: An exploratory subgroup analysis of East Asian (EA) patients in a phase III trial was conducted to
assess efficacy and safety trends based on ethnicity.
Methods: The 795 patients with recurrent or metastatic squamous cell carcinoma of the head and neck
included 111 EA patients randomized to pemetrexed-cisplatin (n = 55) and placebo-cisplatin (n = 56) and
684 non- EA patients randomized to pemetrexed-cisplatin (n = 343) and placebo-cisplatin (n = 341). Treat-
ment differences in median overall survival and progression-free survival were compared using a stratified
log–rank test. Survival was estimated using the Kaplan–Meier method.
Results: The median overall survival in the pemetrexed-cisplatin and placebo-cisplatin arms of the EA
group (6.8 and 5.7 months, respectively [P = 0.275]) was similar to that in the global population (7.3 and
6.3 months, respectively [P = 0.082]); the median progression-free survival in the pemetrexed-cisplatin
and placebo-cisplatin arms in the EA group (2.8 and 1.9 months, respectively [P = 0.748]) was similar to
that in the global population (3.6 and 2.8 months, respectively [P = 0.166]). Compared to the findings in the
global population, overall survival for the EA group receiving prior platinum-based therapy was longer
(P = 0.042 vs P = 0.065). There was no significant interaction between treatment arms and ethnicity.
Conclusion: Consistent with findings in the global population, pemetrexed-cisplatin did not improve
survival compared with placebo-cisplatin for the EA group. However, in a subgroup analysis, pemetrexed-
cisplatin showed an overall survival advantage in EA patients receiving prior platinum-based therapy.
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INTRODUCTION
Squamous cell carcinoma of the head and neck
(SCCHN) – a heterogeneous collection of epithelial
malignancies arising in the upper aerodigestive tract –
is the sixth most common cancer worldwide and
accounts for an estimated 650 000 new cases and
350 000 deaths every year.1,2 Because patients with
recurrent and metastatic SCCHN are generally incur-
able, treatment goals are the prolongation of overall
survival (OS) or progression-free survival (PFS), the pal-
liation of existing symptoms and the prevention of new
cancer-related symptoms.3,4
Among the multiple chemotherapeutic agents that
induce tumor responses, cisplatin is frequently used to
treat patients with inoperable recurrent or metastatic
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SCCHN, either as a monotherapy or in combination
with other chemotherapeutic agents.4,5 The median sur-
vival with cisplatin combination chemotherapy ranges
from approximately 8 to 9 months, with a correspond-
ing 1-year survival rate of approximately 30 to 40 per-
cent.6,7 Pemetrexed, an inhibitor of thymidylate synthase
and other folate-dependent enzymes,8–10 has been inves-
tigated in patients with SCCHN11,12 and other solid
tumors.13–17 In a Phase III trial in patients with SCCHN,
pemetrexed-cisplatin showed OS and PFS advantages in
the subset of patients with Eastern Cooperative Oncol-
ogy Group (ECOG) performance status (PS) 0 or 1 or
oropharyngeal cancer.12
Ethnic minorities (South Asian and Chinese groups) in
British Columbia are at higher risk for both oropharyn-
geal cancer and oral cavity cancer among men and oral
cavity cancer among women.18 The pathogenesis of
SCCHN in some Asian countries is somewhat different
from that in other areas of the world; it is known to be
related to betel quid chewing, which is considered a
poor prognostic factor.19,20 In a cohort analysis, the
increase in the incidence of oropharyngeal cancer in
Taiwan was proposed to be heavily influenced by the
increase in the consumption of alcohol and the use of
betel quid.21 Due to the unique pathogenesis of SCCHN
in some Asian countries, the aim of this exploratory
analysis of an East Asian (EA) patient group in a global
phase III trial was to assess possible trends in efficacy or
safety based on ethnicity.
METHODS
Study design and treatment plan
We performed an exploratory analysis of the random-
ized, double-blind, placebo-controlled, phase III, global
trial reported by Urba et al.12 In this trial, 795 patients
with recurrent or metastatic SCCHN and no prior
systemic therapy for metastatic disease were enrolled
and randomly assigned to pemetrexed plus cisplatin
(pemetrexed-cisplatin; n = 398) or placebo plus cisplatin
(placebo-cisplatin; n = 397).12 Patients received peme-
trexed 500 mg/m2 (10-min infusion) plus cisplatin
75 mg/m2 or placebo (100 mL saline) plus cisplatin
75 mg/m2 on day 1 every 21 days thereafter. Chemo-
therapy was administered for six cycles; patients could
be discontinued from the study before the completion
of the six cycles for disease progression, unacceptable
toxicity, or the decision of patient or physician, or
both. Additional cycles were permitted for patients
showing a benefit from the study treatment. All patients
were followed up until death or the closure of the
study. Details on the study design and treatment were
described previously.12 Only patients enrolled in China,
Korea and Taiwan were considered EA (n = 111, 14%)
and were included in the subgroup analysis reported
here. The non-EA group included a total of 684 patients
(pemetrexed-cisplatin, n = 343 and placebo-cisplatin,
n = 341).
The original trial12 was conducted according to the
Declaration of Helsinki and good clinical practice guide-
lines and was approved by each participating institu-
tional and its ethical review board. All patients signed a
written informed consent from before treatment.
Baseline and treatment assessments
Details of the tumor assessments have been previously
reported.12 Palpable tumors were measured within 2
weeks of the first treatment. For each patient the
imaging method used at baseline was also used for each
assessment throughout the study. Tumor assessments
were repeated every other cycle and every 6 weeks after
treatment discontinuation until disease progression.
Patients who had baseline imaging and at least one scan
after starting chemotherapy were considered assessable
for tumor response using response evaluation criteria in
solid tumors 1.0.22 OS and PFS analyses incorporated all
randomized patients on an intent to treat (ITT) basis.
Patients were assessed for toxicity before each cycle
according to the common terminology criteria for
adverse events, vers. 3.0.23 All patients who received at
least one dose of pemetrexed or cisplatin were consid-
ered assessable for safety.12
Statistical analyses
In the original trial,12 the primary efficacy measure was
OS. Secondary end-points included PFS, tumor response
rate and safety assessment.12 In this report OS, PFS,
tumor response rate and toxicities between treatment
arms in the EA group were compared. In addition,
analyses of the selected subgroups, including stratifica-
tion factors in the EA group, were also performed. The
analyses in the EA group used the same methodology as
was used in the global population.12 The analyses for
this study are underpowered due to the small sample
size; therefore, the data are considered exploratory. Due
to the exploratory nature of the analyses, the P-values
were not adjusted for multiplicity.
To compare the time-to-event end-points (including
the primary end-point, OS), a stratified log–rank test at
a two-sided a = 0.05 was used, with the following prog-
nostic factors as stratification variables: ECOG PS (0/1
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vs 2), previously treated for SCCHN (no vs yes), distant
metastasis (no vs yes) and prior platinum-based therapy
(no vs yes). The Kaplan–Meier method was used to
estimate survival distributions.24 To obtain treatment
effect after adjusting for the prognostic variables, sup-
portive analyses were conducted using the Cox regres-
sion model.25 All efficacy analyses were performed on
ITT patients in the EA group. Patients who had at least
one dose of study treatment were included in the safety
analyses.
Exploratory subgroup analyses for OS and PFS were
conducted on selected subgroups of EA patients: ECOG
PS (0/1 vs 2), previously treated SCCHN (no vs yes),
prior platinum-based therapy (no vs yes), distant
metastasis (no vs yes), age (<65 vs 65 years), sex (male
vs female), primary site of disease (oral cavity, orophar-
ynx, hypopharynx, larynx, and other) and prior surgery
or radiotherapy within 6 months of randomization
(no vs yes). These stratification factors are considered to
be potential prognostic factors; therefore, the random-
ization was done with these stratification factors to
ensure balance in treatment allocation. An unstratified
log–rank test was used to assess the treatment difference
within subgroups and the Cox regression model was
used to test the treatment-by-subgroup interaction.
Tumor responses were compared between treatments
using unadjusted normal approximation for differences
in rates. The incidences of toxicities were analyzed using
Fisher’s exact test.
RESULTS
Patients and treatment
Of the 795 patients randomized to pemetrexed-cisplatin
(n = 398) or placebo-cisplatin (n = 397),12 111 EA
patients (14% [China, n = 12; Korea, n = 53; Taiwan,
n = 46]; pemetrexed-cisplatin, n = 55; placebo-cisplatin,
n = 56) were included in the subgroup analyses re-
ported here. The non-EA group included a total of
684 patients (pemetrexed-cisplatin, n = 343; placebo-
cisplatin, n = 341). Among EA patients the patients’
baseline characteristics, disease characteristics, and
disease sites were comparable between treatment arms
(Table 1). These data are similar to those reported for
the global population;12 therefore, the EA group is rep-
resentative of the global population. There were some
differences in patients’ characteristics between the EA
group and the non-EA group with respect to sex, previ-
ous treatment for SCCHN, prior platinum-based
therapy, and oral cavity as the primary site of disease
(Table 1). In the EA group, 49 percent of patients in the
pemetrexed-cisplatin arm and 36 percent of patients in
the placebo-cisplatin arm received prior platinum-based
therapy; in the non-EA group, 46 percent of patients in
the pemetrexed-cisplatin arm and 44 percent of patients
in the placebo-cisplatin arm received prior platinum-
based therapy. In the global population, 47 percent of
patients in the pemetrexed-cisplatin arm received prior
platinum-based therapy compared with 43 percent
of patients in the placebo-cisplatin arm.12 The oral
cavity was the primary site of disease in both treatment
arms in the EA group (pemetrexed-cisplatin, 49%;
placebo-cisplatin, 43%) and the global population
(pemetrexed-cisplatin, 35%; placebo-cisplatin, 31%).12
Efficacy
The analysis of the primary end-point, OS, was con-
ducted for the EA group. The OS for patients in the
pemetrexed-cisplatin arm was not significantly different
relative to patients in the placebo-cisplatin arm (Fig. 1a).
The median OS times were 6.8 and 5.7 months for
the pemetrexed-cisplatin and placebo-cisplatin arms,
respectively (hazard ratio [HR] = 0.85; 95% confidence
interval [CI] = 0.56–1.30; P = 0.275) (Fig. 1a). These
were similar to the median OS times in the global popu-
lation pemetrexed-cisplatin (7.3 months) and placebo-
cisplatin (6.3 months) arms (P = 0.082).12
An analysis of PFS, a secondary end-point, was also
conducted for the EA group. Themedian PFS times in the
EA group were 2.8 and 1.9 months for the pemetrexed-
cisplatin and placebo-cisplatin arms, respectively (HR =
0.89; 95% CI = 0.59–1.35; P = 0.748) (Fig. 1b). The
median PFS times in the global population were 3.6 and
2.8 months for the pemetrexed-cisplatin and placebo-
cisplatin arms, respectively (P = 0.166).12
Exploratory subgroup analyses showed that, among
EA patients with an ECOG PS of 0 or 1, the median
OS was 8.2 months for patients in the pemetrexed-
cisplatin arm and 6.3 months for patients in the
placebo-cisplatin arm (HR = 0.78; 95% CI = 0.48–1.26;
P = 0.302) (Fig. 1c, Table 2). However, in the global
population, ECOG PS of 0 or 1 patients treated with
pemetrexed-cisplatin led to a significantly longer median
OS (8.4 months) than patients treated with placebo-
cisplatin (6.7 months) (HR = 0.83; 95% CI = 0.70–
0.98; P = 0.026).12 The EA patients with ECOG PS 2
had a median OS of 3.7 months in the pemetrexed-
cisplatin arm and 4.7 months in the placebo-cisplatin
arm (P = 0.688) (Table 2). Similarly, in the global popu-
lation, the ECOG PS 2 subgroup had a median OS of 3.5
months in the pemetrexed-cisplatin arm and 3.3 months
in the placebo-cisplatin arm (P = 0.243).12
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Among EA patients with an ECOG PS of 0 or 1,
the median PFS was 2.9 months for patients in the
pemetrexed-cisplatin arm and 2.6 months for patients
in the placebo-cisplatin arm (HR = 0.91; 95% CI =
0.6–1.4; P = 0.688) (Fig. 1d). In contrast, in the global
population, in patients with an ECOG PS 0 or 1,
pemetrexed-cisplatin led to significantly longer PFS than
placebo-cisplatin (P = 0.044).12 Among EA patients
with ECOG PS 2, the median PFS was 1.5 months for
the pemetrexed-cisplatin arm and 1.4 months for the
placebo-cisplatin arm (P = 0.565). In the global popula-
tion, the ECOG PS 2 subgroup had a median PFS of 1.6
months for the pemetrexed-cisplatin arm and 1.8
months for the placebo-cisplatin arm (P = 0.070).
In the subgroup of EA patients who received prior
platinum-based therapy, the median OS was 4.8 months
longer in the pemetrexed-cisplatin arm than in the
placebo-cisplatin arm (10.3 months vs 5.5 months,
respectively) (HR = 0.49; 95% CI = 0.24–0.99; P =
0.042) (Table 2). However, in the subgroup of the global
population receiving prior platinum-based therapy,
the between-group difference in median OS was not
significant (pemetrexed-cisplatin, 7.5 months; placebo-
cisplatin, 6.6 months; HR = 0.80; 95% CI = 0.63–1.01;
P = 0.065).
In preplanned subgroup analyses involving all EA
patients and EA patients in the PS 0 or 1 subgroup,
OS and PFS seem to favor pemetrexed-cisplatin over
Table 1 Baseline and disease characteristics of the East Asian and non-East Asian group
Characteristic
East Asian Non-East Asian
Pem-cis
(n = 55)
Placebo-cis
(n = 56)
Pem-cis
(n = 343)
Placebo-cis
(n = 341)
Age, years
Median 54.4 57.6 57.7 57.9
Range 37–76 33–72 32–79 21–84
Sex, n (%)
Male 51 (93) 53 (95) 291 (85) 291 (85)
Female 4 (7) 3 (5) 52 (15) 50 (14.7)
Ethnicity, n (%)
African 0 (0.) 0 (0) 17 (5) 12 (3.5)
Caucasian 0 (0) 0 (0) 243 (71) 233 (68)
East Asian 53 (96) 56 (100) 2 (0.6) 9 (3)
Hispanic 0 (0) 0 (0) 11 (3) 16 (5)
Indian 2 (4) 0 (0) 70 (20) 70 (21)
ECOG PS, n (%)
0 or 1 45 (82) 46 (82) 302 (88) 297 (87)
2 10 (18) 10 (18) 41 (12) 43 (13)
Previously treated for HNC, n (%)
Yes 48 (87) 46 (82) 315 (92) 312 (92)
No 7 (13) 10 (18) 28 (8) 29 (9)
Prior platinum-based therapy, n (%)
Yes 27 (49) 20 (36) 158 (46) 149 (44)
No 28 (51) 36 (64) 185 (54) 192 (56)
Distant metastasis, n (%)
Yes 34 (62) 33 (59) 199 (58) 209 (61)
No 21 (38) 23 (41) 144 (42) 132 (39)
Primary site of disease, n (%)
Oral cavity 27 (49) 24 (43) 111 (32) 99 (29)
Larynx 11 (20) 13 (23) 92 (27) 89 (26)
Oropharynx 10 (18) 6 (11) 76 (22) 100 (29)
Hypopharynx 7 (13) 10 (18) 56 (16) 49 (14)
Other 0 (0) 3 (5) 8 (2) 4 (1)
Cis, cisplatin; ECOG, Eastern Cooperative Oncology Group; HNC, head and neck cancer; n, number of patients in group; pem, pemetrexed;
PS, performance status.
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placebo-cisplatin across most of the groups (all
HR < 1.00) (Tables 3 and 4).
The objective response rate in the EA group was 15
percent in the pemetrexed-cisplatin arm compared with
11 percent in the placebo-cisplatin arm (P = 0.543);
all were partial responses. Stable disease rate in the
EA group was 29 percent in the pemetrexed-cisplatin
arm compared with 18 percent in the placebo-cisplatin
arm; progressive disease rate was 38 percent in the
pemetrexed-cisplatin arm compared with 55 percent
in the placebo-cisplatin arm. Similarly, the objective
response rate in the non-EA group was 12 percent
in the pemetrexed-cisplatin arm compared with 8
percent in the placebo-cisplatin arm (P = 0.074).
The stable disease rate in the non-EA group was 40
percent in the pemetrexed-cisplatin arm compared
with 36.7 percent in the placebo-cisplatin arm, and
the progressive disease rate was 11 versus 7 percent,
respectively. Likewise, in the global population, the
tumor response rate (complete response and partial
response) was not significantly different between
treatment arms (pemetrexed-cisplatin, 12%; placebo-
cisplatin, 8%; P = 0.061).12
The Cox regression analysis showed that the prognos-
tic factor of an ECOG PS of 0 or 1 had a significant
effect on OS (PS 0 or 1 vs PS 2; HR = 0.43; 95%
CI = 0.25–0.74; P = 0.002) and PFS (PS 0 or 1 vs PS 2;
HR = 0.56; 95% CI = 0.33–0.93; P = 0.025). In addi-
tion, significant prognostic effects on OS were demon-
strated in subgroups previously treated for SCCHN
(not treated for SCCHN vs treated; HR = 0.49; 95%
CI = 0.26–0.95; P = 0.034.) and prior platinum-based
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Figure 1 Kaplan–Meier plots of overall survival (OS) and progression-free survival (PFS) for East Asian group and Eastern
Cooperative Oncology Group performance status (PS) 0 or 1 subgroup showing (a) OS; (b) PFS; (c) OS for group with performance
status 0 or 1; and (d) PFS for group with PS 0 or 1. Cis, cisplatin; Pem, pemetrexed. . —, placebo + cis; – —, pem + cis.
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therapy (not treated with platinum vs treated;
HR = 1.69; 95% CI = 1.03–2.78; P = 0.038). It is
important to note that the subset analyses of the EA
group are underpowered.
The median OS times for the non-EA group were
7.4 and 6.3 months for the pemetrexed-cisplatin and
placebo-cisplatin arms, respectively. The median PFS
times for the non-EA group were 3.9 months and
3.1 month for the pemetrexed-cisplatin and placebo-
cisplatin arm, respectively. Subgroup analyses of the EA
group (pemetrexed-cisplatin, n = 55; placebo-cisplatin,
n = 56) versus the non-EA group (pemetrexed-cisplatin,
n = 343; placebo-cisplatin, n = 341) showed no signifi-
cant interactions between both treatment arms or
between the EA versus non-EA groups in the OS
outcome (interaction P = 0.817) or the PFS outcome
(interaction P = 0.984). In other words, the pemetrexed-
cisplatin benefits in OS and PFS in the EA and non-EA
groups subgroups were similar.
More EA patients discontinued treatment in the
placebo-cisplatin arm due to progressive disease (38
[68%]) compared with those in the pemetrexed-cisplatin
arm (29 [53%]).
Post-discontinuation therapy
In the EA group, 37 (66%) patients in the placebo-
cisplatin arm received systemic post-discontinuation
therapy, whereas 27 (49%) patients in the pemetrexed-
cisplatin arm received systemic post-discontinuation
therapy.
Safety
In the EA group, drug-related grade 3 or 4 laboratory
toxicities in the pemetrexed-cisplatin arm compared
with the placebo-cisplatin arm included neutropenia
(11 vs 2%), anemia (6 vs 2%) and thrombocytopenia
(4 vs 12%); drug-related grade 3 or 4 non-laboratory
toxicity in the pemetrexed-cisplatin arm compared with
the placebo-cisplatin arm included nausea (4 vs 2%).
None of the between-group differences were significant
(Table 5).
In the non-EA group, drug-related grade 3 or 4
laboratory toxicities in the pemetrexed-cisplatin arm
compared with the placebo-cisplatin arm included
neutropenia (12 vs 3%), anemia (11 vs 4%), leukopenia
(10 vs 1%) and thrombocytopenia (4 vs 2%) (Table 5).
The between-group differences for neutropenia, anemia
and leukopenia were significant. In the non-EA group,
drug-related grade 3 or 4 non-laboratory toxicities the
pemetrexed-cisplatin arm compared with the placebo-
cisplatin arm included fatigue (6 vs 2%; P = 0.026) and
febrile neutropenia (3 vs 0%; P = 0.001). In the global
population, patients in the pemetrexed-cisplatin arm
exhibited a significantly higher incidence of drug-related
grade 3 or 4 laboratory toxicities and drug-related grade
3 or 4 non-laboratory toxicities compared with those in
the placebo-cisplatin arm.12
In the EA group, 10 (19%) patients in the
pemetrexed-cisplatin arm and four (8%) patients in
the placebo-cisplatin arm died during therapy or within
30 days of treatment discontinuation. In the global
Table 2 Analyses of overall survival for the subgroup of East Asian patients (ITT population)
Subgroup
Pem-cis (n = 55) Placebo-cis (n = 56)
P-value HR (95% CI)n (%)
Median OS
(months) n (%)
Median OS
(months)
ECOG performance status
0 or 1 45 (82) 8.2 46 (82) 6.3 0.302 0.78 (0.48–1.26)
2 10 (18) 3.7 10 (18) 4.7 0.688 1.21 (0.48–3.00)
Previously treated for HNC
Yes 48 (87) 6.8 46 (82) 5.5 0.149 0.71 (0.44–1.13)
No 7 (13) 3.4 10 (18) 9.6 0.385 1.62 (0.54–4.89)
Distant metastasis
Yes 34 (62) 5.1 33 (59) 5.7 0.917 0.97 (0.57–1.66)
No 21 (38) 9.8 23 (41) 5.9 0.226 0.64 (0.31–1.32)
Prior platinum-based therapy
Yes 27 (49) 10.3 20 (36) 5.5 0.042 0.49 (0.24–0.99)
No 28 (51) 4.8 36 (64) 7.5 0.485 1.21 (0.70–2.10)
CI, confidence interval; Cis, cisplatin; ECOG, Eastern Cooperative Oncology Group; HNC, head and neck cancer; HR, hazard ratio of pem + cis over
placebo + cis; ITT, intent to treat; n, number of patients in group; OS, overall survival; Pem, pemetrexed.
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population, 92 (24%) patients in the pemetrexed-
cisplatin arm and 96 (25%) patients in the placebo-
cisplatin arm died during therapy or within 30 days of
treatment discontinuation.12 One (2%) patient in the
pemetrexed-cisplatin arm in the EA group died due to
study drug toxicity (acute renal failure/sepsis).
DISCUSSION
This is an exploratory subgroup analysis involving the
EA group in the recently reported phase III, randomized,
double-blind trial comparing pemetrexed-cisplatin to
placebo-cisplatin in patients with inoperable recurrent
or metastatic SCCHN.12 As observed in the global study
population, patients in the pemetrexed-cisplatin arm did
not show significant improvements in OS and PFS com-
pared with patients on cisplatin monotherapy in the EA
group. However, the between-arm differences in OS and
PFS in the EA group were similar to those reported in
the global population, suggesting there was no impact
from ethnicity on the study results.
Overall, the tumor response rate (complete response
and partial response) results were consistent across
the EA and global populations.12 Similarly, the tumor
response rates in the EA and non-EA groups were
similar. In a more restricted analysis confined to the
group with an ECOG PS of 0 or 1, which comprised
82 percent of EA patients, pemetrexed-cisplatin treat-
ment was associated with improved OS compared with
placebo-cisplatin. This improvement in OS was not sta-
tistically significant compared with placebo-cisplatin;
however, the between-arm differences in OS and PFS
Table 3 Subgroup analyses of overall survival for East Asian patients with Eastern Cooperative Oncology Group performance
status of 0 or 1
Subgroup
Pem-cis (n = 45) Placebo-cis (n = 46)
P-value HR (95% CI)n (%)
Median OS
(months) n (%)
Median OS
(months)
Previously treated for head and neck cancer
Yes 39 (87) 8.2 40 (87) 5.6 0.101 0.65 (0.4–1.1)
No 6 (13) 6.4 6 (13) 11.4 0.329 1.92 (0.5–7.2)
Distant metastasis
Yes 28 (62) 5.5 25 (54) 8.0 0.945 0.98 (0.5–1.8)
No 17 (38) 9.8 21 (46) 5.6 0.086 0.50 (0.2–1.1)
Prior platinum-based therapy
Yes 19 (42) 11.4 17 (37) 5.5 0.011 0.34 (0.1–0.8)
No 26 (58) 5.0 29 (63) 8.0 0.497 1.23 (0.7–2.2)
Prior surgery or radiotherapy within
6 months of randomization
Yes 10 (22) 9.8 9 (20) 5.2 0.145 0.44 (0.1–1.4)
No 35 (78) 6.8 37 (80) 7.2 0.687 0.90 (0.5–1.5)
Primary site of disease
Oral cavity 22 (49) 8.9 23 (50) 5.3 0.109 0.57 (0.3–1.1)
Larynx 10 (22) 6.8 10 (22) 8.1 0.804 1.15 (0.4–3.5)
Oropharynx 9 (20) 9.7 3 (7) 9.6 0.443 0.57 (0.1–2.4)
Hypopharynx 4 (9) 2.5 8 (17) 9.2 0.003† 14.13 (1.5–129.5)
Other NA NA 2 (4) 2.9 NA NA
Age
<65 33 (73.3) 9.7 39 (85) 6.7 0.18 0.69 (0.4–1.2)
65 12 (26.7) 5.0 7 (15) 5.7 0.612 1.31 (0.5–3.7)
Sex
Male 41 (91.1) 8.2 44 (96) 6.3 0.261 0.75 (0.5–1.2)
Female 4 (8.9) 8.3 2 (4) . 0.896† 1.17 (0.1–11.4)
Race
Non-Caucasian 45 (100.0) 8.2 46 (100.0) 6.3 0.302 0.78 (0.5–1.3)
†P-value should be interpreted with caution as the sample size is very small. CI, confidence interval; cis, cisplatin; HR, hazard ratio of pem + cis over
placebo + cis; n, number of patients in group; NA, not assessable; OS, overall survival; pem, pemetrexed.
Pemetrexed + cisplatin in SCCHN 337
© 2013 Wiley Publishing Asia Pty LtdAsiaPac J Clin Oncol 2013; 9: 331–341
were statistically significant in patients in the global
population with an ECOG PS of 0 or 1.12 It is possible
that the sample size of the EA group was not large
enough to achieve statistical significance.
In the subgroup analyses, in EA patients with an
ECOG PS of 0 or 1, there was no significant difference
in OS and PFS between the pemetrexed-cisplatin
and placebo-cisplatin arms (P = 0.302 and P = 0.688,
respectively); in contrast, in patients with an ECOG
PS of 0 or 1 in the global population, pemetrexed-
cisplatin or placebo-cisplatin led to significantly longer
OS (P = 0.026) and PFS (P = 0.044) than placebo-
cisplatin.12 It is important to note that these findings
could be due to the relatively small sample size of the EA
group and the exploratory nature of the analysis.
In the subgroup analysis involving EA patients with
an ECOG PS of 0 or 1, as expected, the median OS in
patients with PS 0 or 1 in the pemetrexed-cisplatin arm
(8.2 months) versus that for patients in the placebo-
cisplatin arm (6.3 months) contrasts with the median OS
in patients with PS 2 receiving the same treatments (3.7
months vs 4.7 months, respectively).
The Cox regression analysis showed that an ECOG PS
of 0 or 1 had a significant and perhaps clinically relevant
effect onOS (P = 0.002) and PFS (P = 0.025), confirming
that an ECOG PS of 0 or 1 was a prognostic factor in this
study. These results emphasize that the benefit of pemetr-
exed plus cisplatin in the EA group with advanced
SCCHN is primarily observed in patients with a good
ECOG PS (0 or 1). It is also important to note that the
relatively low number of patients with ECOG PS 2 (18%
of the EA patients) may have negatively impacted on the
results in the EA group. These results are consistent with
those obtained in the global population.12
Table 4 Subgroup analyses of progression-free survival for East Asian patients with Eastern Cooperative Oncology Group
performance status of 0 or 1
Subgroup
Pem-cis (n = 45) Placebo-cis (n = 46)
P-value HR (95% CI)n (%)
Median PFS
(months) n (%)
Median PFS
(months)
Previously treated for head and neck cancer
Yes 39 (87) 2.9 40 (87) 2.7 0.633 0.88 (0.5–1.5)
No 6 (13) 2.4 6 (13) 1.5 0.886 1.10 (0.3–3.9)
Distant metastasis
Yes 28 (62) 2.8 25 (54) 1.9 0.756 0.91 (0.5–1.7)
No 17 (38) 3.6 21 (46) 2.7 0.791 0.91 (0.4–1.9)
Prior platinum-based therapy
Yes 19 (42) 3.8 17 (37) 2.7 0.401 0.72 (0.3–1.6)
No 26 (58) 2.9 29 (63) 1.6 0.875 1.05 (0.6–1.9)
Prior surgery or radiotherapy within
6 months of randomization
Yes 10 (22) 2.9 9 (20) 1.2 0.994 1.00 (0.4–2.8)
No 35 (78) 3.2 37 (80) 2.7 0.611 0.87 (0.5–1.5)
Primary site of disease
Oral cavity 22 (49) 2.8 23 (50) 2.4 0.255 0.70 (0.4–1.3)
Larynx 10 (22) 4.2 10 (22) 5.7 0.268 2.16 (0.5–8.7)
Oropharynx 9 (20) 4.9 3 (7) 4.4 0.654 1.62 (0.2–13.7)
Hypopharynx 4 (8.9) 1.2 8 (17) 2.2 0.015† 7.38 (1.2–44.5)
Other NA NA 2 (4) 1.5 NA NA
Age (years)
<65 33 (73) 3.6 39 (89) 1.6 0.324 0.77 (0.5–1.3)
65 12 (27) 1.6 7 (15) 2.7 0.199 2.12 (0.7–6.8)
Sex
Male 41 (91) 2.9 44 (96) 2.7 0.972 0.99 (0.6–1.6)
Female 4 (9) 3.4 2 (4) 1.7 0.107† 0.17 (0.0–1.9)
Race
Non-Caucasian 45 (100) 2.9 46 (100) 2.6 0.688 0.91 (0.6–1.4)
†P-value should be interpreted with caution as the sample size is very small. CI, confidence interval; cis, cisplatin; HR, hazard ratio of pem + cis over
placebo + cis; n, number of patients in group; NA, not assessable; pem, pemetrexed; PFS, progression-free survival.
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These findings confirm that PS is a prognostic
factor12,26–28 and highlight the importance of PS as a
reliable parameter that may be used as an inclusion
criterion in clinical trials. PS has long been considered
the most important prognostic factor for patients
with SCCHN. A PS of 0 or 1 has been associated with a
better OS in patients with advanced SCCHN.29 In a
clinical trial involving patients with advanced SCCHN,
response and survival were related to PS.30 In addition,
the oral cavity, which is considered a poor prognostic
factor, was the primary site of disease in both treatment
arms in the EA, non-EA and global populations.12
In preplanned subgroup analyses involving all EA
patients and EA patients in the ECOG PS 0 or 1 sub-
groups, OS and PFS seem to favor pemetrexed-cisplatin
over placebo-cisplatin across most of the groups (all
HR < 1.00), but the between-group differences were not
statistically significant. Nonetheless, these differences
may be potentially clinically relevant: it is possible that
the small sample sizes explained the failure to achieve
statistical significance.
The toxicity profile of pemetrexed-cisplatin in this
subgroup analysis in the EA group did not show any
unexpected toxicities. In the global12 and EA groups,
drug-related grade 3 or 4 laboratory toxicities included
neutropenia, anemia, thrombocytopenia and leukope-
nia. However, in contrast with the findings in the global
population,12 the between-group differences in neutro-
penia, anemia, and leukopenia in the EA group were not
significant, possibly because the sample sizes were too
small to achieve statistical significance. In contrast with
the findings in the EA group, the incidence of anemia
and fatigue was numerically higher and the between-
treatment group differences were statistically significant
in the non-EA group, indicating that toxicity in SCCHN
treatment may vary among patients of different ethnic
origins. Nonetheless, the toxicity profile of pemetrexed-
cisplatin was consistent with the known toxicity profile
in other tumor types.13,14
In conclusion, consistent with the findings in the
global population, pemetrexed-cisplatin, as compared
with placebo-cisplatin, did not improve survival for
the EA group. Pemetrexed-cisplatin treatment led to
improved OS in the EA group with an ECOG PS of 0 or
1 compared with placebo-cisplatin, but these results
were not significant. However, the between-arm differ-
ences in OS and PFS were statistically significant in favor
of pemetrexed-cisplatin in the global population with an
ECOG PS of 0 or 1.12 In contrast with the findings in
the global population, pemetrexed-cisplatin showed an
OS advantage in EA patients who had received prior
platinum-based therapy.12 Overall, the observations
made in the EA group provide an insight in planning
future global studies, especially patient selection, which
is considered to be as important as the type of treat-
ment selection. Although the various prognostic and
Table 5 Patients with selected Common Terminology Criteria for Adverse Events grade 3 or 4 drug-related toxicities (worst grade)
in East Asian and non-East Asian groups†
Toxicity
East Asian Non-East Asian
Pem-cis
(n = 54)
Placebo-cis
(n = 53)
P-value
Pem-cis
(n = 338)
Placebo-cis
(n = 332)
P-valuen (%) n (%) n (%) n (%)
Laboratory
Neutropenia 6 (11) 1 (12) 0.113 39 (12) 9 (3) < 0.001
Anemia 3 (6) 1 (2) 0.618 37 (11) 12 (4) < 0.001
Leukopenia 1 (2) 1 (2) >0.999 32 (10) 4 (1) < 0.001
Thrombocytopenia 2 (4) 1 (2) >0.999 13 (4) 5 (2) 0.092
Non-laboratory
Fatigue 0 (0) 0 (0) NA 19 (6) 7 (2) 0.026
Febrile neutropenia 1 (2) 0 (0) >0.999 11 (3) 0 (0) 0.001
Nausea 2 (4) 1 (2) >0.999 8 (2) 9 (3) 0.811
Vomiting 0 (0) 2 (2) 0.243 8 (2) 8 (2) > 0.999
Anorexia 1 (2) 2 (2) 0.618 7 (2) 4 (1) 0.546
Diarrhea 0 (0) 0 (0) NA 5 (2) 0 (0) 0.062
Renal failure 1 (2) 0 (0) >0.999 4 (1) 5 (2) 0.750
†Selection of grade 3 or 4 adverse events was based on those reported in Urba et al.12. Cis, cisplatin; n, number of patients with event; NA, not
assessable; pem, pemetrexed.
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disease-related factors are well balanced in the EA group
relative to those in the overall population,12 caution
should be used in interpreting the results of the EA
subgroup analysis due to the underpowered, explor-
atory nature of these analyses.
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